Skip to main content
Fig. 7 | The Journal of Headache and Pain

Fig. 7

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 7

Change in MSQoL domain scores in A) participants aged ≥60 years and B) overall population. MSQoL, Migraine-specific Quality of Life; RFR, role-function restrictive; RFP, role-function preventive; EF, emotional function; LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. Data shown are the LSM changes from baseline in MSQoL domain scores at Week 12. aP < 0.05 vs placebo. bP < 0.0005 vs placebo. cP < 0.01 vs placebo. dP < 0.0001 vs placebo

Back to article page